Jefferies Group LLC Analysts Give Sanofi SA (SAN) a €86.00 Price Target
Sanofi SA (EPA:SAN) has been given a €86.00 ($102.38) price target by stock analysts at Jefferies Group LLC in a research report issued to clients and investors on Monday. The firm currently has a “neutral” rating on the stock.
Other equities research analysts have also recently issued research reports about the company. Morgan Stanley set a €91.00 ($108.33) price objective on Sanofi SA and gave the company a “buy” rating in a research note on Tuesday, June 6th. Credit Suisse Group set a €95.00 ($113.10) target price on Sanofi SA and gave the company a “buy” rating in a report on Tuesday, July 4th. Kepler Capital Markets set a €89.00 ($105.95) target price on Sanofi SA and gave the company a “buy” rating in a report on Wednesday, July 26th. Deutsche Bank AG set a €96.00 ($114.29) target price on Sanofi SA and gave the company a “buy” rating in a report on Tuesday, August 1st. Finally, J P Morgan Chase & Co set a €90.00 ($107.14) target price on Sanofi SA and gave the company a “neutral” rating in a report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. Sanofi SA has a consensus rating of “Hold” and a consensus price target of €87.81 ($104.54).
Sanofi SA (SAN) opened at 81.55 on Monday. The stock has a 50 day moving average of €26.12 and a 200-day moving average of €25.99. Sanofi SA has a 12-month low of €24.55 and a 12-month high of €81.60. The company has a market capitalization of €102.41 billion and a PE ratio of 11.38.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.